Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q3 2026 · 10-Q
Revenue$4.35M$4.35M+22.0% vs Q3 2025 Net Income-$819.00K-$819.00KN/M vs Q3 2025 EPS Diluted-$0.48-$0.48N/M vs Q3 2025 Gross Profit$1,650,000+29.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$764,000N/M Free Cash Flowderived-$811,000N/M Margins · derivedGross margin37.9%+2.3 pt vs Q3 2025
Operating margin-15.6%+13.3 pt vs Q3 2025
Net margin-18.8%+7.2 pt vs Q3 2025
ended Dec 31, 2025 · filed Feb 10, 2026 · 41 d after period end